Europe Next-Generation Sequencing Market Trends & Summary
Market Overview
The Europe Next-Generation Sequencing (NGS) market is projected to reach US$12.95 billion by 2032, growing from US$4.58 billion in 2023 at a CAGR of 12.24% during the 2024–2032 period. This growth is driven by advancements in genomic research, the rising adoption of personalized medicine, and the increasing prevalence of genetic diseases.
Free Download Sample Report: https://www.renub.com/request-sample-page.php?gturl=united-states-next-generation-sequencing-market-p.php
Market Segmentation
The Europe NGS Market is categorized based on products, applications, technology, end-users, and country-wise analysis.
By Products:
- Instruments
- Reagents & Consumables
- Services
By Applications:
- Diagnostics
- Agriculture and Animal Research
- Drug Discovery
- Personalized Medicine and Genetic Screening
- Others
By Technology:
- Sequencing by Synthesis
- Ion Semiconductor Sequencing
- Single-Molecule Real-Time Sequencing
- Nanopore Sequencing
- Others
By End-Users:
- Academic and Clinical Research Centers
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Others
By Country:
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Russia
- Poland
- Greece
- Norway
- Romania
- Portugal
- Turkey
- Rest of Europe
Market Outlook
Advancements in Genomic Research
Technological improvements in sequencing have led to faster, more accurate, and cost-effective sequencing techniques, enabling biotech firms and research institutions to advance in personalized medicine, rare disease analysis, and oncology.
Rising Incidence of Genetic Disorders
With the growing prevalence of genetic diseases, rare disorders, and inherited cancers, demand for NGS-based diagnostics is increasing. NGS facilitates accurate genetic data analysis for better treatment and management of these conditions.
Expanding Applications in Personalized Medicine
NGS is crucial in the development of personalized medicine, where treatments are tailored based on a patient’s genetic profile. With increased adoption by European healthcare facilities, investment in NGS solutions is fueling market growth.
Market Challenges
High Implementation Costs
NGS instruments and reagents remain expensive, posing a challenge for small-scale research institutions and public healthcare facilities to adopt the technology.
Data Privacy and Regulatory Challenges
Europe’s strict GDPR regulations on genomic data security create challenges in data management and cross-border research collaboration.
Key Market Segments
Europe NGS Instruments Market
The demand for high-throughput sequencing in research and clinical applications is growing. However, high costs and skilled personnel requirements remain challenges. Leading players include Illumina and Oxford Nanopore Technologies.
Europe NGS Diagnostics Market
NGS is transforming disease detection and personalized medicine, particularly for cancer, genetic disorders, and infectious diseases. Despite growing adoption, regulatory challenges and reimbursement policies slow down the implementation of new tests.
Europe NGS by Synthesis Market
NGS-SBS, dominated by Illumina, is a widely adopted sequencing method due to its scalability and cost-effectiveness. However, high costs of reagents and the need for advanced bioinformatics solutions hinder mass adoption.
Europe NGS in Hospitals and Clinics
Hospitals increasingly use NGS for cancer diagnostics, rare disease identification, and personalized treatments. Challenges include high equipment costs, lack of trained professionals, and slow reimbursement processes.
Country-wise Market Analysis
France
- Government-backed initiatives like France Genomic Medicine Plan 2025 are boosting NGS adoption.
- NewBiologix SA launched an NGS and optical mapping platform in April 2024 to advance genomic analysis.
Germany
- Germany is a leader in genomics and biotechnology investments.
- Government subsidies and grants encourage high-throughput sequencing adoption.
- Germany’s NGS segment is set to dominate European research applications in 2024.
- Data from the German Center for Lung Research (July 2024) reveals that 2,500 newborns were diagnosed with cystic fibrosis in 2022.
Key Market Developments
- July 2024: Belgium launched permanent reimbursement for NGS-based oncology testing.
- June 2024: Illumina Inc. completed the integration of XLEAP-SBS™ chemistry into NextSeq™ 1000 & 2000 instruments.
- May 2024: QIAGEN launched an updated Clinical Insight platform for NGS molecular profiling.
- August 2023: Almac Diagnostic Services expanded NGS capabilities with Illumina NovaSeq™ X Plus in Northern Ireland.
Competitive Landscape
Key players in the European NGS market:
- Illumina
- Thermo Fisher Scientific
- Pacific Biosciences of California
- QIAGEN N.V.
- Roche
- Bio-Rad Laboratories, Inc.
- Takara Bio Inc.
- Hamilton Company
- Geneious
- BioMérieux SA
These companies are engaged in strategic partnerships, acquisitions, and new product launches to strengthen their market position.
Conclusion
The Europe NGS market is poised for significant expansion, driven by advancements in genomic research, personalized medicine, and increasing adoption in clinical settings. While challenges such as high costs and regulatory barriers persist, technological innovations, government funding, and increasing diagnostic applications are expected to propel market growth in the coming years.
About Us
Renub Research is a leading market research and advisory firm with over 15 years of experience in providing business-to-business global market research, business surveys, and management consulting. Our firm is dedicated to offering a comprehensive suite of services tailored to help businesses make informed decisions.
We partner with our clients to identify their greatest opportunities, address pressing issues, and navigate the changes required to drive success. Our clients span across various high-stakes industries such as Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecoms & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture.
Our Expertise
Renub Research is trusted by top global organizations for our deep insights, actionable market information, and precise market data that empower our clients to make well-informed decisions. We are a well-established provider of industry solutions, and our research is pivotal in assisting consultants, bankers, and executives with crafting solid business strategies.
Our team consists of highly skilled professionals with expertise in finance, marketing, human resources, biotechnology, pharmaceuticals, IT, environmental science, and other related fields. The studies we conduct form the foundation of management decisions, including strategies, organizational structures, activities, technology use, and merger and acquisition opportunities.
Why Choose Renub Research?
- Comprehensive Market Insights: Our reports provide detailed information and insights on opportunities and trends across various industries.
- Strategic Analysis: We deliver in-depth analysis, helping companies understand market dynamics and competitive positioning.
- Accurate Forecasting: Our forecast and estimation methodologies ensure that managers have reliable data to make decisions in a rapidly changing global economy.
Leave a Reply